Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI4 | Q9UM07 | 19/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24568634 | 0.92 | PADI4 (0.63) | PADI4 | |
| SCHEMBL24568586 | 0.89 | PADI4 (0.62) | PADI4 | |
| SCHEMBL29642267 | 0.89 | PADI4 (0.54) | PADI4 | |
| SCHEMBL24568072 | 0.88 | PADI4 (0.57) | PADI4 | |
| SCHEMBL29642237 | 0.88 | PADI4 (0.57) | PADI4 | |
| SCHEMBL29642375 | 0.87 | PADI4 (0.58) | PADI4 | |
| SCHEMBL24568544 | 0.87 | PADI4 (0.58) | PADI4 | |
| SCHEMBL24568070 | 0.87 | PADI4 (0.56) | PADI4 | |
| SCHEMBL24568571 | 0.87 | PADI4 (0.55) | PADI4 | |
| SCHEMBL24568446 | 0.85 | PADI4 (0.76) | PADI4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4267587-A2 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | Gilead Sciences, Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20220227787-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2022-07-21 | — | — | US | disclosed |
| WO-2022140428-A2 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140428-A2 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227787-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | PADI4, PADI2, PADI1 | PADI4 1/4885 |
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | PADI4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.